---
title: "Retension Pharmaceuticals falls 9% during regular trading"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303444144.md"
description: "Retension Pharmaceuticals fell 8.88% to US$12.32. Down 15.52% over five sessions."
datetime: "2026-10-28T19:46:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303444144.md)
  - [en](https://longbridge.com/en/news/303444144.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303444144.md)
generator: "portal-rs"
---

# Retension Pharmaceuticals falls 9% during regular trading

Retension Pharmaceuticals (RTSN.US) fell nearly **9%** during regular trading to **$12.32**.

The stock is down 15.52% over the past five sessions and sits 33.91% below its 52-week high of US$18.64. The intraday swing reached 11.50%.

The Nasdaq Composite is down 0.73% over the past five sessions and up 14.06% year to date.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [RTSN.US](https://longbridge.com/en/quote/RTSN.US.md)

## Related News & Research

- [Retension Pharma director Franklin M. Berger acquires 10,000 common shares for $120,000](https://longbridge.com/en/news/301760599.md)
- [Retension Pharmaceuticals adopts amended and restated bylaws ahead of IPO close](https://longbridge.com/en/news/301750965.md)
- [Anthropic’s Valuation Target Has Slipped From $2 Trillion to Under $1.5 Trillion. Here’s Why](https://longbridge.com/en/news/305493732.md)
- [MaxLinear Stock In Focus After New AI Optics Power Chip Launch](https://longbridge.com/en/news/305513238.md)
- [Analyst Shrugs Off Nebius Data Center Delay As 'Slight Blemish' on Strong Quarter](https://longbridge.com/en/news/305494332.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**